The long-term treatment of social phobia with moclobemide
The DOI matches its Crossref record.
Abstract
Patients meeting the social phobia criteria of the revised third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) on the DSM-III-R Structured Clinical Interview (n = 101) entered a long-term moclobemide treatment study. These patients were treated for 2 years with moclobemide (phase I) followed by drug withdrawal, in most cases abruptly (phase II). Those who relapsed entered phase III for a further period of 2 years of treatment. During phase I 40 patients (39.6%) withdrew due to inefficacy or relapse. Two patients were removed from the study because of other diagnoses (borderline or schizophreniform). At the end of phase I the remaining patients (58.4%) were rated as not ill (45.5%) or minimally ill (11.9%). Effort was taken to achieve the maximum dose of moclobemide (750 mg/day) and the mean (+/-SD) dose was 723.3 +/- 67.7 mg/day (month 21). A marked decrease in symptoms in the patients who responded was recorded on the Liebowitz Scale for Social Phobia, Clinical Global Impressions. Hamilton Anxiety Scale and Hamilton Depression Scale. Non-response was mainly associated with co-morbidity, especially alcohol abuse, axis II disorders, and a history of major depression or secondary dysthymia. The drug was well tolerated; the more frequent side effects were mild and occurred mainly in the first 2 months of phase I, including nausea, headaches or insomnia. In phase II there was a relapse rate of 88% and 51 patients entered phase III; these patients are still being treated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Update on Bispectral Index monitoring
Johansen, J. W. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2005.08.004 · Cited by 313
Romero, L. M., & Remage-Healey, L. (2000) · General and Comparative Endocrinology · doi:10.1006/gcen.2000.7491 · Cited by 259
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment
Brunello, N., den Boer, J. A., Judd, L. L., Kasper, S., Kelsey, J. E., Lader, M., Lecrubier, Y., Lepine, J. P., Lydiard, R. B., Mendlewicz, J., et al. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00140-8 · Cited by 153
“…MAOIs brofaromine (Van Vliet et al., 1992, Fahlen et al., 1995, Slaap et al., 1996 and Lott et al., 1997) and moclobemide (Versiani et al., 1992 and Versiani et al., 1996) have also demonstrated superiority to placebo in some, but not all (Noyes et al., 1997 and Schneier et al., 1998),…”
BackgroundMassion, A. O., Dyck, I. R., Shea, M. T., Phillips, K. A., Warshaw, M. G., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.434 · Cited by 149
Practical guide for prescribing MAOIs: debunking myths and removing barriers
Grady, M. M., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s109285291200003x · Cited by 51
Metadata
- Authors
- Versiani, M., Nardi, A. E., Mundim, F. D., Pinto, S., Saboya, E., & Kovacs, R.
- Venue
- International Clinical Psychopharmacology
- Published
- 1996-06
- Volume
- 11
- Issue
- Supplement 3
- Pages
- 83-88
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2001168479
- Cited by
- 79
- References
- 0
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The long-term treatment of social phobia with moclobemide. https://app.cochat.ai/papers/10.1097/00004850-199606003-00014
- The paper
- Versiani, M., Nardi, A. E., Mundim, F. D., Pinto, S., Saboya, E., & Kovacs, R. (1996). The long-term treatment of social phobia with moclobemide. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199606003-00014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.